How Many Dexamethasone Doses Should Be Given Perioperatively?
NCT06715709
Recruiting
The purpose of this study is to determine the most efficient and safest dexamethasone dose given perioperatively during total knee arthroplasty that reduces postoperative option consumption and pain, improves postoperative nausea and vomiting, and minimizes postoperative complications
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/14/2025
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Arthropathy of Knee
Register for Updates
The Effect of a Methylprednisolone Taper on Outcomes Following Total Knee Arthroplasty
NCT06489626
Not Yet Recruiting
Pain control and early range of motion following total knee arthroplasty are essential for patient satisfaction. Intraoperative steroids (dexamethasone) have been shown to have a significant effect in controlling acute pain following total knee arthroplasty. This study aims to evaluate the effect of a post-operative steroid (methylprednisolone) taper in improving functional and patient-reported outcomes following total knee arthroplasty. A taper means taking a high dose of a medication followed... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/12/2025
Locations: UPMC East, Monroeville, Pennsylvania +1 locations
Conditions: Arthritis Knee, Knee Osteoarthritis, Pain, Postoperative
Register for Updates
Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis
NCT04847453
Recruiting
This phase I/Ia trial finds the best dose and side effects of venetoclax given in combination with ixazomib citrate and dexamethasone in treating patients with light chain amyloidosis that has come back (relapsed) or does not respond to treatment (refractory) and who have an abnormal genetic change \[translocation t(11;14)\]. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer c... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/11/2025
Locations: City of Hope Comprehensive Cancer Center LAO, Duarte, California +16 locations
Conditions: AL Amyloidosis
Register for Updates
A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT04910568
Active Not Recruiting
This Phase Ib, multicenter, open-label study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of cevostamab monotherapy, cevostamab plus pomalidomide and dexamethasone (Pd) or cevostamab plus daratumumab and dexamethasone (Dd) which will be administered to participants with relapsed or refractory multiple myeloma (R/R MM) via intravenous (IV) infusion.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/10/2025
Locations: City of Hope, Duarte, California +29 locations
Conditions: Multiple Myeloma
Register for Updates
A Phase I/II Study of CAR.70-Engineered IL15-Transduced Cord Blood-Derived NK Cells With TGF-beta Receptor 2 (TGFBR2) Knock Out in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Myeloid Malignancies
NCT06930651
Not Yet Recruiting
The goal of this clinical research study is to find the recommended safe dose of TGFBR2 KO CAR27/IL-15 NK cells that can be given to patients with relapsed/refractory disease. The safety and effectiveness of this treatment will also be studied.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
04/09/2025
Locations: The University of Texas M. D. Anderson Cancer Center, Houston, Texas
Conditions: Myeloid Malignancies
Register for Updates
Dexamethasone for Ureteral STent Symptoms (DUSTS)
NCT06930690
Not Yet Recruiting
The purpose of this study to learn if high-dose dexamethasone, a type of long-acting steroid, works to decrease urinary symptoms and pain after ureteroscopy and stent placement for kidney stones. The main question it aims to answer is: 1) Does high-dose steroid change the quality of life score on day 2 after surgery Researchers will compare high-dose of dexamethasone (20 mg) to a standard dose of dexamethasone (4 mg) to see if a higher dose of the drug will help with urinary symptoms and pain... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
04/09/2025
Locations: Houston Methodist Hospital, Houston, Texas
Conditions: Ureteral Stent-Related Symptom
Register for Updates
A Study of Treatment of Inflammation Before Stem Cell Transplant in People With a Primary Immune Regulatory Disorder (PIRD) and/or an Autoinflammatory Condition
NCT05787574
Recruiting
The researchers are doing this study to find out whether emapalumab or a combination of fludarabine and dexamethasone are effective in preparing people with a primary immune regulatory disorder (PIRD) and/or an autoinflammatory condition to receive a stem cell transplant. The researchers will look at how well the study treatments reduce inflammation and aid in the engraftment process (the process of donated stem cells traveling to the bone marrow, where they begin to make new immune cells. "Fun... Read More
Gender:
ALL
Ages:
All
Trial Updated:
04/09/2025
Locations: University of California, San Francisco (Data collection only), San Francisco, California +9 locations
Conditions: Primary Immune Regulatory Disorder, Autoimmune Lymphoproliferative, Immune System Diseases
Register for Updates
Anterior Femoral and Adductor Canal Nerve Blocks in Peds Knees
NCT06590402
Recruiting
The goal of this pilot clinical trial is to compare anterior femoral cutaneous nerve block (AFCN) to adductor canal block ACB) for pediatric patients undergoing either anterior cruciate ligament (ACL) or medial patellofemoral ligament (MPFL). The aims of this trial are: * To measure postoperative functional outcomes in patients who received AFCNB vs. ACB. * To calculate postoperative opioid requirements in pediatric knee surgeries that received AFCNB vs. ACB. * To calculate pain intensity level... Read More
Gender:
ALL
Ages:
Between 8 years and 18 years
Trial Updated:
04/09/2025
Locations: Hospital for Special Surgery, New York, New York
Conditions: Anterior Cruciate Ligament Reconstruction, Medial Patellofemoral Ligament Reconstruction
Register for Updates
Carfilzomib Based Chemotherapy Mobilization for Autologous Stem Cell Transplants in Multiple Myeloma
NCT03909412
Recruiting
This phase I study utilizes a 3+3 design with escalating cohorts of Carfilzomib at 20mg/m2, 27mg/m2, 36mg/m2, 45mg/m2, 56mg/m2, and 70mg/m2 to be administered concomitantly with Cyclophosphamide 2 gm/m2, Dexamethasone and Granulocyte colony-stimulating factor (G-CSF)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/04/2025
Locations: Hackensack Meridian Health - John Theurer Cancer Center, Hackensack, New Jersey
Conditions: Multiple Myeloma
Register for Updates
Subclinical Primary Aldosteronism in Diabetes At-Risk for Kidney Disease
NCT06190158
Recruiting
The aim of this protocol is to assess the presence and severity of primary aldosteronism pathophysiology in patients with type 2 diabetes who have, or are at-risk for developing, chronic kidney disease.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
04/03/2025
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Type 2 Diabetes, Chronic Kidney Diseases
Register for Updates
Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMM
NCT04052880
Active Not Recruiting
This is a single center, open-label, phase 2 study in elderly (age ≥ 70) subjects with newly diagnosed multiple myeloma who are transplant ineligible. Subjects will receive subcutaneous daratumumab, dose-attenuated bortezomib, revlimid, and dexamethasone until confirmed disease progression, discontinuation of study treatment due to unacceptable drug toxicity, or other reasons. Throughout the study, subjects will be monitored closely for adverse events, laboratory abnormalities, and clinical resp... Read More
Gender:
ALL
Ages:
70 years and above
Trial Updated:
04/03/2025
Locations: Icahn School of Medicine at Mount Sinai, New York, New York
Conditions: Newly Diagnosed Multiple Myeloma
Register for Updates
Dexamethasone in Total Knee Arthroplasty
NCT05018091
Active Not Recruiting
The purpose of this study is to determine the most efficacious and safest dexamethasone dose given intraoperatively during total knee arthroplasty that reduces postoperative opioid consumption and pain, improves postoperative nausea and vomiting, and minimizes postoperative complications.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/02/2025
Locations: Stanford University, Redwood City, California +9 locations
Conditions: Total Knee Arthroplasty
Register for Updates